ARS Pharmaceuticals Inc. (SPRY)
ARS Pharmaceuticals Statistics
Share Statistics
ARS Pharmaceuticals has 98.12M shares outstanding. The number of shares has increased by 1.26% in one year.
| Shares Outstanding | 98.12M |
| Shares Change (YoY) | 1.26% |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | 73.45% |
| Shares Floating | 56.04M |
| Failed to Deliver (FTD) Shares | 7.59K |
| FTD / Avg. Volume | 0.45% |
Short Selling Information
The latest short interest is 17.15M, so 17.48% of the outstanding shares have been sold short.
| Short Interest | 17.15M |
| Short % of Shares Out | 17.48% |
| Short % of Float | 32.59% |
| Short Ratio (days to cover) | 6.54 |
Valuation Ratios
The PE ratio is 127.87 and the forward PE ratio is -27.1. ARS Pharmaceuticals's PEG ratio is -1.12.
| PE Ratio | 127.87 |
| Forward PE | -27.1 |
| PS Ratio | 11.47 |
| Forward PS | 2.2 |
| PB Ratio | 3.98 |
| P/FCF Ratio | 78.76 |
| PEG Ratio | -1.12 |
Enterprise Valuation
ARS Pharmaceuticals has an Enterprise Value (EV) of 971.91M.
| EV / Sales | 10.9 |
| EV / EBITDA | -315.25 |
| EV / EBIT | 71.74 |
| EV / FCF | 74.85 |
Financial Position
The company has a current ratio of 14.26, with a Debt / Equity ratio of 0.
| Current Ratio | 14.26 |
| Quick Ratio | 14.04 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 3.11% and Return on Invested Capital is -0.91%.
| Return on Equity | 3.11% |
| Return on Assets | 2.28% |
| Return on Invested Capital | -0.91% |
| Revenue Per Employee | $575.15K |
| Profits Per Employee | $51.6K |
| Employee Count | 155 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 288K |
| Effective Tax Rate | 3.48% |
Stock Price Statistics
The stock price has increased by 76.54% in the last 52 weeks. The beta is 0.98, so ARS Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | 76.54% |
| 50-Day Moving Average | 12.18 |
| 200-Day Moving Average | 12.74 |
| Relative Strength Index (RSI) | 66.38 |
| Average Volume (20 Days) | 1.68M |
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 89.15M and earned 8M in profits. Earnings per share was 0.08.
| Revenue | 89.15M |
| Gross Profit | 89.15M |
| Operating Income | -3.08M |
| Net Income | 8M |
| EBITDA | -3.08M |
| EBIT | -3.08M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 50.82M in cash and 42K in debt, giving a net cash position of 50.77M.
| Cash & Cash Equivalents | 50.82M |
| Total Debt | 42K |
| Net Cash | 50.77M |
| Retained Earnings | -123.31M |
| Total Assets | 351.15M |
| Working Capital | 310.86M |
Cash Flow
In the last 12 months, operating cash flow was 13.55M and capital expenditures -563K, giving a free cash flow of 12.98M.
| Operating Cash Flow | 13.55M |
| Capital Expenditures | -563K |
| Free Cash Flow | 12.98M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 100%, with operating and profit margins of -3.46% and 8.97%.
| Gross Margin | 100% |
| Operating Margin | -3.46% |
| Pretax Margin | 9.29% |
| Profit Margin | 8.97% |
| EBITDA Margin | -3.46% |
| EBIT Margin | -3.46% |
| FCF Margin | 14.57% |
Dividends & Yields
SPRY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.78% |
| FCF Yield | 1.27% |
Analyst Forecast
The average price target for SPRY is $29, which is 94.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $29 |
| Price Target Difference | 94.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 9.8 |
| Piotroski F-Score | 6 |